Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMPASS Pathways plcCMPS · Entity 4567 | Director | May 27, 2026 | May 29, 2026 |
| Design Therapeutics, Inc.DSGN · Entity 4991 | Director | June 09, 2026 | June 11, 2026 |
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | June 01, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMPASS Pathways plc
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2036-05-26 | Direct | 21,110 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 21,110 · Balance 21,110 F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Design Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-08 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.
Xenon Pharmaceuticals Inc.
Report date June 01, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 2,645 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Exercise / conversion · Acquired 2,645 · Balance 2,645 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Exercise / conversion · Disposed 2,645 · Balance 0 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,593 |
Reported balance
After 2026-06-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-03 · Grant · Acquired 1,593 · Balance 1,593 F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.46 · Expires 2036-06-02 | Direct | 10,507 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 10,507 · Balance 10,507 F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 222,773 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Justin D. Gover 2020 Irrevocable Trust dated December 14, 2020 | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 456,048 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy the Gover Family Investment LLP | 0 |
Reported balance
After 2021-05-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-05-05 · Disposition to issuer · Disposed 1,867,308 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-03-15 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-05 · Disposition to issuer · Disposed 17,508 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $10.61 · Expires 2025-06-24 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-05 · Disposition to issuer · Disposed 75,864 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2026-02-15 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-05 · Disposition to issuer · Disposed 213,240 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.81 · Expires 2027-01-06 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-05 · Disposition to issuer · Disposed 142,344 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2028-02-26 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-05 · Disposition to issuer · Disposed 147,624 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-05-05 · Disposition to issuer · Disposed 119,472 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.65 · Expires 2029-06-14 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-05-05 · Disposition to issuer · Disposed 30,936 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-05-05 · Disposition to issuer · Disposed 22,440 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-05-05 · Disposition to issuer · Disposed 34,008 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-05-05 · Disposition to issuer · Disposed 226,752 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-05-05 · Disposition to issuer · Disposed 12,492 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-05-05 · Disposition to issuer · Disposed 55,488 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2021-05-05 · Disposition to issuer · Disposed 287,904 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2021-05-05 · Disposition to issuer · Disposed 479,844 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2021-05-05 · Disposition to issuer · Disposed 164,496 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2021-05-05 · Disposition to issuer · Disposed 263,184 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.
F5: These stock options were granted with automatic vesting on exercisable date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2019 Filed Jun 19, 2019 01:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 55,488 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-017352 · doc4.xml · derivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,488 Underlying: Ordinary Shares · 55,488 shares Expires 2023-03-15 F5 · security: Performance based stock options granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 14, 2019. Read SEC document |
| June 14, 2019 Filed Jun 19, 2019 01:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 30,936 | $0.00 Strike: $14.65 | $0.00 |
DisclosureSEC source: 0000899243-19-017352 · doc4.xml · derivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,936 Underlying: Ordinary Shares · 30,936 shares Expires 2029-06-14 F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F4 · derivative.exercise_price: The exercise price reported is price per ordinary share converted from price per ADS ($175.74). Read SEC document |
| June 14, 2019 Filed Jun 19, 2019 01:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantOrdinary Shares | 16,656 | $0.00 | $21.65 |
DisclosureSEC source: 0000899243-19-017352 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,197 F1 · shares: Grant of restricted stock units ("RSUs") pursuant to the Issuer's Long-Term Incentive Plan, which will vest automatically in four equal annual installments beginning on June 14, 2020. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 14, 2019. Read SEC document |
| May 28, 2019 Filed May 31, 2019 00:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 202,224 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-015228 · doc4.xml · derivative · entry 8 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,231 Underlying: Ordinary Shares · 202,224 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 28, 2019. Read SEC document |
| May 28, 2019 Filed May 31, 2019 00:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 6,012 | $15.49 | $93,125.88 |
DisclosureSEC source: 0000899243-19-015228 · doc4.xml · nonDerivative · entry 7 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,541 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F9 · price: The price reported in Column 4 is a weighted average price per ordinary share ($185.87 per ADS). These shares were sold in multiple transactions at prices ranging from $185.78 per ADS (or $15.48 per ordinary share) to $185.95 per ADS (or $15.50 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2019 Filed May 31, 2019 00:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 19,284 | $15.43 | $297,552.12 |
DisclosureSEC source: 0000899243-19-015228 · doc4.xml · nonDerivative · entry 6 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,553 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F8 · price: The price reported in Column 4 is a weighted average price per ordinary share ($185.15 per ADS). These shares were sold in multiple transactions at prices ranging from $184.73 per ADS (or $15.39 per ordinary share) to $185.64 per ADS (or $15.47 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2019 Filed May 31, 2019 00:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 40,728 | $15.35 | $625,174.80 |
DisclosureSEC source: 0000899243-19-015228 · doc4.xml · nonDerivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,837 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F7 · price: The price reported in Column 4 is a weighted average price per ordinary share ($184.18 per ADS). These shares were sold in multiple transactions at prices ranging from $183.69 per ADS (or $15.31 per ordinary share) to $184.65 per ADS (or $15.39 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2019 Filed May 31, 2019 00:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 56,736 | $15.25 | $865,224.00 |
DisclosureSEC source: 0000899243-19-015228 · doc4.xml · nonDerivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,565 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F6 · price: The price reported in Column 4 is a weighted average price per ordinary share ($183.05 per ADS). These shares were sold in multiple transactions at prices ranging from $182.69 per ADS (or $15.22 per ordinary share) to $183.66 per ADS (or $15.31 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2019 Filed May 31, 2019 00:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 26,784 | $15.17 | $406,313.28 |
DisclosureSEC source: 0000899243-19-015228 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664,301 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F5 · price: The price reported in Column 4 is a weighted average price per ordinary share ($182.08 per ADS). These shares were sold in multiple transactions at prices ranging from $181.66 per ADS (or $15.14 per ordinary share) to $182.64 per ADS (or $15.22 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2019 Filed May 31, 2019 00:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 52,680 | $15.08 | $794,414.40 |
DisclosureSEC source: 0000899243-19-015228 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,085 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F4 · price: The price reported in Column 4 is a weighted average price per ordinary share ($180.92 per ADS). These shares were sold in multiple transactions at prices ranging from $180.57 per ADS (or $15.05 per ordinary share) to $181.56 per ADS (or $15.13 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2019 Filed May 31, 2019 00:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 202,224 | $0.00 | $262.89 |
DisclosureSEC source: 0000899243-19-015228 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 28, 2019. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 30,334 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008407 · doc4.xml · derivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,668 Underlying: Ordinary Shares · 30,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of March 15, 2018. F7 · derivative.exercise_date: The reported transaction related to exercise of stock options to purchase 30,334 shares which vested on February 15, 2018. The remaining stock options vest equally on February 15, 2019 and 2020, and will expire 13 months after vesting date. F7 · derivative.expiration_date: The reported transaction related to exercise of stock options to purchase 30,334 shares which vested on February 15, 2018. The remaining stock options vest equally on February 15, 2019 and 2020, and will expire 13 months after vesting date. F7 · balance_after: The reported transaction related to exercise of stock options to purchase 30,334 shares which vested on February 15, 2018. The remaining stock options vest equally on February 15, 2019 and 2020, and will expire 13 months after vesting date. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 17,517 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008407 · doc4.xml · derivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,517 shares Expires 2019-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of March 15, 2018. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 23,400 | $14.01 | $327,834.00 |
DisclosureSEC source: 0000899243-19-008407 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,541 F5 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. F6 · price: The price reported in Column 4 is a weighted average price per ordinary share ($168.09 per ADS). These shares were sold in multiple transactions at prices ranging from $167.59 per ADS (or $13.97 per ordinary share) to $168.54 per ADS (or $14.05 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerOrdinary Shares | 19 | $13.88 | $263.72 |
DisclosureSEC source: 0000899243-19-008407 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,941 F4 · price: The price reported in Column 4 is price per ordinary share converted from price per ADS. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 47,851 | $0.00 | $62.21 |
DisclosureSEC source: 0000899243-19-008407 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. Following the exercise, 47,832 of these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of March 15, 2018. F3 · balance_after: Includes (a) 67,320 ordinary shares underlying restricted stock units previously reported as stock options on Table II of the reporting person's Form 3 filed on October 1, 2018, of which 22,440 shares will vest automatically on February 26, 2020, 2021 and 2022, respectively and (b) 68,016 ordinary shares underlying restricted stock units previously reported as stock options on Table II of the reporting person's Form 4 filed on March 5, 2019, of which 17,004 shares will automatically vest on March 1, 2020, 2021, 2022 and 2023, respectively. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:07 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 17,004 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006336 · doc4.xml · derivative · entry 6 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,004 Underlying: Ordinary Shares · 17,004 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:07 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 17,004 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006336 · doc4.xml · derivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,004 Underlying: Ordinary Shares · 17,004 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:07 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 17,004 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006336 · doc4.xml · derivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,004 Underlying: Ordinary Shares · 17,004 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:07 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 17,004 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006336 · doc4.xml · derivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,004 Underlying: Ordinary Shares · 17,004 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:07 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 226,752 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006336 · doc4.xml · derivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,752 Underlying: Ordinary Shares · 226,752 shares Expires 2023-03-15 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:07 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 119,472 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0000899243-19-006336 · doc4.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,472 Underlying: Ordinary Shares · 119,472 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · security: The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · derivative.exercise_price: The exercise price reported is price per ordinary share converted from price per ADS ($172.01). Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 22,440 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005260 · doc4.xml · derivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,440 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 96 | $12.28 | $1,178.88 |
DisclosureSEC source: 0000899243-19-005260 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,773 F3 · shares: These ordinary shares are represented by ADSs. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 11,016 | $12.45 | $137,149.20 |
DisclosureSEC source: 0000899243-19-005260 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,869 F3 · shares: These ordinary shares are represented by ADSs. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 22,440 | $0.00 | $29.17 |
DisclosureSEC source: 0000899243-19-005260 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. Following the exercise, these shares were converted into 1,870 American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 22,620 | $12.50 | $282,750.00 |
DisclosureSEC source: 0000899243-19-003848 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,445 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. F2 · shares: These ordinary shares are represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. The reporting person acquired these shares on December 20, 2018 in connection with an exercise of options that were due to expire on December 24, 2018. F3 · price: The price reported in Column 4 is price per ordinary share ($150.0 per ADS). Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 1,200 | $8.52 | $10,224.00 |
DisclosureSEC source: 0000899243-19-000526 · doc4.xml · nonDerivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,065 F1 · shares: These ordinary shares are represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F6 · price: The price reported in Column 4 is price per ordinary share ($102.25 per ADS). Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 14,220 | $8.43 | $119,874.60 |
DisclosureSEC source: 0000899243-19-000526 · doc4.xml · nonDerivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,265 F1 · shares: These ordinary shares are represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F5 · price: The price reported in Column 4 is a weighted average price per ordinary share ($101.13 per ADS). These shares were sold in multiple transactions at prices ranging from $100.64 per ADS (or $8.39 per ordinary share) to $101.63 per ADS (or $8.47 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 1,200 | $8.25 | $9,900.00 |
DisclosureSEC source: 0000899243-19-000526 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,485 F1 · shares: These ordinary shares are represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F4 · price: The price reported in Column 4 is price per ordinary share ($99.00 per ADS). Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 3,600 | $8.14 | $29,304.00 |
DisclosureSEC source: 0000899243-19-000526 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,685 F1 · shares: These ordinary shares are represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported in Column 4 is a weighted average price per ordinary share ($97.69 per ADS). These shares were sold in multiple transactions at prices ranging from $97.14 per ADS (or $8.10 per ordinary share) to $97.97 per ADS (or $8.16 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 2,400 | $7.96 | $19,104.00 |
DisclosureSEC source: 0000899243-19-000526 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,285 F1 · shares: These ordinary shares are represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: The price reported in Column 4 is price per ordinary share ($95.51 per ADS). Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 45,240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031706 · doc4.xml · derivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 45,240 shares Expires 2018-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.2662 U.S. Dollars as of December 20, 2018. F3 · shares: Exercise of stock options. Following the exercise, these shares were converted into 3,770 ADSs. F4 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan and fully vested. F3 · derivative.underlying_shares: Exercise of stock options. Following the exercise, these shares were converted into 3,770 ADSs. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 45,240 | $0.00 | $58.81 |
DisclosureSEC source: 0000899243-18-031706 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. These ordinary shares are represented by 3,770 American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.2662 U.S. Dollars as of December 20, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.